SCHEMBL5344405

SCHEMBL5344405

NCCOCCOC(=O)CO

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.37
ALDH1A1 P00352 4/20 0.37
TP53 P04637 2/20 0.37
HIF1A Q16665 2/20 0.37
HSD17B10 Q99714 1/20 0.37
SERPINE1 P05121 1/20 0.34
ADRA2A P08913 1/20 0.32
ADRA1A P35348 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPT P10636 2/20 0.31
CHRM2 P08172 2/20 0.31
CHRM4 P08173 2/20 0.31
CHRM5 P08912 2/20 0.31
CHRM1 P11229 2/20 0.31
CHRM3 P20309 2/20 0.31
CYP2C19 P33261 2/20 0.31
BLM P54132 1/20 0.31
LMNA P02545 1/20 0.31
HTR1A P08908 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3385884 0.88 TSHR (0.44) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL5351821 0.85
SCHEMBL18274688 0.84 ALDH1A1 (0.38) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL6560315 0.81 MEN1 (0.55) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL20913720 0.81 MEN1 (0.55) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL822271 0.81 MEN1 (0.55) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL28519535 0.80 NAAA (0.47) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL26669487 0.80 NAAA (0.47) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL243060 0.80 ADRA2A (0.43) TSHRALDH1A1TP53HIF1AADRA2A
SCHEMBL26479100 0.78 TSHR (0.34) TSHRALDH1A1TP53HIF1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279304-B2 Methods for preparation of macrocyclic molecules and macrocyclic molecules prepared thereby PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-10-09 US claimed
US-20020192773-A1 Methods for preparation of macrocyclic molecules and macrocyclic molecules prepared thereby THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2002-12-19 US claimed
US-7279304-B2 Methods for preparation of macrocyclic molecules and macrocyclic molecules prepared thereby PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-10-09 US disclosed
WO-2003040094-A9 METHODS FOR PREPARATION OF MACROCYCLIC MOLECULES MACROCYCLIC MOLECULES PREPARED THEREBY AND SUBSTRATES AND SOLID SUPPORTS FOR USE THEREIN HARVARD COLLEGE (US) 2004-04-15 WO disclosed
US-20030158377-A1 Methods for preparation of macrocyclic molecules macrocyclic molecules prepared thereby and substrates and solid supports for use therein PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2003-08-21 US disclosed
WO-2003040094-A2 METHODS FOR PREPARATION OF MACROCYCLIC MOLECULES MACROCYCLIC MOLECULES PREPARED THEREBY AND SUBSTRATES AND SOLID SUPPORTS FOR USE THEREIN PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2003-05-15 WO disclosed
US-20020192773-A1 Methods for preparation of macrocyclic molecules and macrocyclic molecules prepared thereby THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158377-A1 Methods for preparation of macrocyclic molecules macrocyclic molecules prepared thereby and substrates and solid supports for use therein VIP, ZKSCAN2, TEC TSHR 2263/4885ALDH1A1 4602/4885TP53 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.